Attorney Docket: 39262-330604

PT-2707-US-PCT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Currently Amended) A biodegradable segmented block copolymer comprising polyol

residues, wherein in that the polyol residues have a molecular weight of at least 4000

Daltons, wherein and in that the polyol residues are connected by acetal linkages, and

wherein the polyol residues are selected from the group consisting of polyesters,

degradable carbonates, and polyamides.

2. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the acetal linkages comprise polyacetal residues.

3. (Currently Amended) The biodegradable segmented block copolymer of claim

2, wherein in which the polyacetal residues comprise enzyme degradable

polyacetal/diamino acid ester blocks.

4. (Currently Amended) The biodegradable segmented block copolymer of claim 2,

wherein in which the polyacetal residues comprise an incorporated bioactive diol.

5. (Currently Amended) The biodegradable segmented block copolymer of claim 2.

wherein in which the polyacetal residues comprise both enzyme degradable

polyacetal/diamino acid ester blocks and incorporated bioactive agent.

6. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the segmented block copolymer is blended with other polymeric and/or

ceramic and/or glass material.

Attorney Docket: 39262-330604

PT-2707-US-PCT

7. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in-which the polyol residues have a molecular weight of at least 5000 Daltons.

8. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the polyol residues have a molecular weight between 4000 and 20000

Daltons.

9. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein the in which polyol residues comprise a polyester polyesters.

10. (Currently Amended) The biodegradable segmented block copolymer of claim 9,

wherein in which the polyester is chosen selected from the group[[:]] consisting of homo-

polymers and co-polymers of polycaprolactone (PCL), copolymers of polycaprolactone

(PCL), polylactic acid (PLA, L and D forms), polyglycolic acid (PGA), polydioxanone,

aliphatetic aliphatic esters or and aromatic esters ester.

11. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the polyol residues comprise comprises a degradable carbonate.

12. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the polyol residues comprise a polyamide.

13. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the biodegradable segmented block copolymer further comprises a

compound selected from the group[[:]] consisting of polyglycolic acid (PGA),

polycaprolactone (PCL) or and polylactic acid (PLA).

5 of 23

Attorney Docket: 39262-330604

PT-2707-US-PCT

14. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the biodegradable segmented block copolymer further comprises a

biocompatible inorganic material.

15. (Currently Amended) The biodegradable segmented block copolymer of claim 14,

wherein in which the biocompatible inorganic material is selected from the group

consisting of [[:]] calcium carbonate, hydroxyapitite (HA), and or tricalcium phosphate

(TCP).

16. (Currently Amended) [[A]] The biodegradable segmented block copolymer of claim 1,

wherein in which the polyol residue comprises a polyester polyesters with a melting point

between about 50°C and 80°C.

17. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which a stabilizer or accelerator is blended into or polymerized into the

biodegradable segmented block copolymer.

18. (Currently Amended) The biodegradable segmented block copolymer of claim 1, further

comprising in which the segmented block copolymer comprises whether blended in or

reacted with or other, a biological active agent blended in or reacted with the segmented

block copolymer.

19. (Currently Amended) The biodegradable segmented block copolymer of claim 18,

wherein said biological active agent is selected from the group consisting of a growth

factor, an antibiotic, a strontium salt, a fluoride salt, a magnesium salt, a sodium salt, a

bone morphogenetic factor, a chemotherapeutic agent, a pain killer, a bisphosphonate, a

bone growth agent, an angiogenic factor, and combinations thereof.

6 of 23

Attorney Docket: 39262-330604

PT-2707-US-PCT

20. (Currently Amended) The biodegradable segmented block copolymer of claim 19,

wherein said biological agent comprises a growth factor and wherein said growth factor

is selected from the group consisting of platelet derived growth factor (PDGF),

transforming growth factor b (TGF-b), insulin-related growth factor-I (IGF-I), insulin-

related growth factor-II (IGF-II), fibroblast growth factor (FGF), beta-2-microglobulin

(BDGF II), bone morphogenetic protein (BMP), and combinations thereof.

21. (Currently Amended) The biodegradable segmented block copolymer of claim 19,

wherein said biological agent comprises an antibiotic and wherein said antibiotic is

selected from the group consisting of tetracycline hydrochloride, vancomycin,

cephalosporins, and aminoglycocides such as tobramycin, gentacin, and combinations

thereof.

22. (Currently Amended) The biodegradable segmented block copolymer of claim 19,

wherein said biological agent comprises a bone growth agent and wherein said bone

growth agent is selected from the group consisting of proteins of demineralised bone,

demineralised bone matrix (DBM), bone protein (BO), bone morphogenetic protein

(BMP), osteonectin, osteocalcin, osteogenin, and combinations thereof.

23. (Currently Amended) The biodegradable segmented block copolymer of claim 19,

wherein said biological agent comprises a chemotherapeutic agent and wherein said

chemotherapeutic agent is selected from the group consisting of cisplatinum, ifosfamide,

methotrexate, doxorubicin hydrochloride, and combinations thereof.

24. (Currently Amended) The biodegradable segmented block copolymer of claim 19,

wherein said biological agent comprises a pain killer and wherein said pain killer is

Attorney Docket: 39262-330604

PT-2707-US-PCT

selected from the group consisting of lidocaine hydrochloride, bipivacain hydrochloride,

non-steroidal anti-inflammatory drugs such as ketorolac tromethamine, and combinations

thereof.

25. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the biodegradable segmented block copolymer further comprises is

reinforced with a reinforcing material.

26. (Currently Amended) The biodegradable segmented block copolymer of claim 25,

wherein in which the reinforcing material is comprises a polymer filler particulate.

27. (Currently Amended) The biodegradable segmented block copolymer of claim 25,

wherein in which the reinforcing material is comprises a fibre.

28. (Cancelled)

29. (Currently Amended) The biodegradable segmented block copolymer of claim 1,

wherein in which the biodegradable segmented block copolymer forms in whole, or part,

a medical device.

30. (Previously Presented) A medical device comprising the biodegradable segmented

block copolymer of claim 1.

31. (Currently Amended) A method of manufacture of a medical device comprising the step

forming *in situ* the biodegradable segmented block copolymer of claim 1.

32. (New) The medical device of claim 30, wherein the biodegradable segmented block

copolymer comprises a coating on the medical device.